Sun-woo Kim

/C O R R E C T I O N -- Deep Bio/

Retrieved on: 
Thursday, February 1, 2024

SEOUL, South Korea, Jan. 31, 2024 /PRNewswire/ -- Deep Bio, a leader in artificial intelligence (AI)-powered cancer diagnostics, proudly announced the availability of its CE-marked in-vitro diagnostic device, DeepDx Prostate, on the Swiss market.

Key Points: 
  • Deep Bio wishes to clarify that DeepDx Prostate has been placed on the Swiss market as a CE-marked in-vitro diagnostic device.
  • DeepDx Prostate is an AI-powered software for the assessment of prostate cancer on digital whole slide images of hematoxylin and eosin-stained prostate core-needle biopsies.
  • "We are excited to introduce DeepDx Prostate to Switzerland," said Sun Woo Kim, the CEO and founder of Deep Bio.
  • Deep Bio continues to expand its global reach through partnerships with digital pathology leaders in the US, Europe, and India.

Deep Bio successfully integrates DeepDx® Prostate algorithm into HALO AP® platform from Indica Labs

Retrieved on: 
Tuesday, August 9, 2022

HALO AP incorporates state-of-the-art workflow management tools allowing users to easily integrate quantitative analytics and AI tools built using HALO, HALO AI and third-party algorithms, such as DeepDx.

Key Points: 
  • HALO AP incorporates state-of-the-art workflow management tools allowing users to easily integrate quantitative analytics and AI tools built using HALO, HALO AI and third-party algorithms, such as DeepDx.
  • To simplify integration, a HALO AP analysis software development kit (SDK) including sample code is available to all algorithm developers.
  • DeepDx Prostate analysis can be triggered directly in HALO AP by selecting the DeepDx workflow or run automatically via the HALO AP API.
  • To learn more about analyzing prostate cores with DeepDx Prostate in HALO AP, contact Deep Bio at [email protected] for a full demonstration.

Deep Bio Wins Approval for World's First AI-based Prostate Cancer Severity Grading Software from Korea MFDS

Retrieved on: 
Wednesday, November 24, 2021

This milestone is Deep Bio's second Korean MFDS regulatory approval, following the clearance of a model for prostate cancer detection last year.

Key Points: 
  • This milestone is Deep Bio's second Korean MFDS regulatory approval, following the clearance of a model for prostate cancer detection last year.
  • DeepDx-Prostate Pro analyzes WSIs (Whole Slide Images) of H&E (Hematoxylin & Eosin) stained prostate core needle biopsies and automatically classifies the histological severity of prostate cancer.
  • "It is deeply meaningful that Deep Bio introduces the world's first clearance of AI technology that aids grading the severity of prostate cancer in pathological tissue diagnosis," stated Sun Woo Kim, the CEO of Deep Bio.
  • Tae Yeoung Kwak, the CTO of Deep Bio said "Deep Bio's AI technology for analyzing prostate cancer has gained a global reputation following presentation in international conferences and academic journals.

Deep Bio and ARUP to Conduct a Prospective Study to Evaluate AI Performance in a Real-World Pathology Workflow

Retrieved on: 
Monday, October 25, 2021

The company will conduct a prospective study to validate the performance of its AI-based prostate cancer diagnosis software, DeepDx Prostate, at ARUP Laboratories, a leading reference laboratory in the US.

Key Points: 
  • The company will conduct a prospective study to validate the performance of its AI-based prostate cancer diagnosis software, DeepDx Prostate, at ARUP Laboratories, a leading reference laboratory in the US.
  • This prospective study is significant in that it validates the overall performance of DeepDx Prostate on real-world patient data," stated Sun Woo Kim, the CEO of Deep Bio.
  • In addition to this study, Deep Bio and ARUP have plans to collaborate on other clinical research related to cancer diagnosis, prognosis, and prediction.
  • Deep Bio Inc. is an AI biotech company with in-house expertise in deep learning, pathology, life sciences, and pharmacotherapeutics.